Cyclin-dependent kinase 4/6 inhibitors and dermatologic adverse events: Results from the EADV task force "Dermatology for cancer patients" international study

Sollena, Pietro; Segura Tigell, Sonia; EADV Task Force

doi:http://dx.doi.org/10.3390/cancers15143658

Cyclin-dependent kinase 4/6 inhibitors and dermatologic adverse events: Results from the EADV task force "Dermatology for cancer patients" international study

Llicència

Citació

Sollena P, Vasiliki N, Kotteas E, Stratigos AJ, Fattore D, Orlandi A, et al. Cyclin-dependent kinase 4/6 inhibitors and dermatologic adverse events: Results from the EADV task force "Dermatology for cancer patients" international study. Cancers (Basel). 2023 Jul 18;15(14):3658. DOI: 10.3390/cancers15143658

Resum

Background: The introduction of cyclin-dependent kinase inhibitors (CDK4/6i) was a great advance in therapeutics for patients with estrogen receptor+/human epidermal growth factor receptor (HER2) locally advanced and metastatic breast cancer. Despite the increasing use of these agents, their adverse drug-related events have not yet been fully characterized. We describe the spectrum of cutaneous adverse reactions occurring in advanced breast cancer patients treated with cyclin-dependent kinase inhibitors, analyzing types, severity, time to onset, and possible treatment outcomes. Methods: We performed a multicentric retrospective study including patients with advanced breast cancer who developed cutaneous lesions during treatment with CDK4/6i in the period from June 2020 to June 2021. Patients > 18 years were recruited at eleven onco-dermatology units located in Albania (1), Argentina (1), France (1), Greece (3), Italy (3), and Spain (2). We evaluated patients' epidemiological and clinical characteristics, types of cutaneous adverse events, their time to onset, and treatment outcomes. The severity of the skin reactions was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 score. Results: Seventy-nine patients (median age: 62.3 years; range 39-83 years) were included in the study, and, collectively, we recorded a total of 165 cutaneous adverse events during follow-up visits. The most frequent cutaneous reactions were pruritus (49/79 patients), alopecia (25/79), and eczematous lesions (24/79). Cutaneous toxicities were usually mild in severity (>65%) and occurred after a median of 6.5 months. Only four patients (5%) required treatment discontinuation due to the severity of the skin lesions. The majority of the skin reactions were managed with topical treatments. Conclusions: To the best of our knowledge, we present the largest case series of cutaneous adverse events developing in advanced breast cancer patients treated with CDK4/6i. We showed that cutaneous toxicities are usually mild in severity, and manageable with standard supportive care; however, in selected cases, they can lead to treatment discontinuation with possible implications for patients' clinical outcomes.